vs
Side-by-side financial comparison of Brookfield Infrastructure Partners L.P. (BIP) and Viatris (VTRS). Click either name above to swap in a different company.
Brookfield Infrastructure Partners L.P. is the larger business by last-quarter revenue ($5.4B vs $3.7B, roughly 1.5× Viatris). On growth, Brookfield Infrastructure Partners L.P. posted the faster year-over-year revenue change (5.7% vs 5.0%).
Brookfield Infrastructure Partners L.P. is a publicly traded limited partnership with corporate headquarters in Toronto, Canada, that engages in the acquisition and management of infrastructure assets on a global basis.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
BIP vs VTRS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4B | $3.7B |
| Net Profit | $252.0M | — |
| Gross Margin | 26.4% | 31.1% |
| Operating Margin | 24.4% | -5.2% |
| Net Margin | 4.6% | — |
| Revenue YoY | 5.7% | 5.0% |
| Net Profit YoY | 37.0% | — |
| EPS (diluted) | $-0.03 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.7B | ||
| Q3 25 | — | $3.7B | ||
| Q2 25 | $5.4B | $3.6B | ||
| Q1 25 | — | $3.2B | ||
| Q4 24 | — | $3.5B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | $5.1B | $3.8B | ||
| Q1 24 | — | $3.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $252.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $184.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | 26.4% | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | 24.6% | 38.2% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | 24.4% | 6.5% | ||
| Q1 25 | — | -88.9% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | 22.8% | -6.3% | ||
| Q1 24 | — | 5.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-0.34 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | $-0.03 | $0.00 | ||
| Q1 25 | — | $-2.55 | ||
| Q4 24 | — | $-0.43 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | $-0.10 | $-0.27 | ||
| Q1 24 | — | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.3B | $1.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $29.6B | $14.7B |
| Total Assets | $108.7B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $975.3M | ||
| Q2 25 | $2.3B | $566.4M | ||
| Q1 25 | — | $755.0M | ||
| Q4 24 | — | $734.8M | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | $1.3B | $917.2M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $14.7B | ||
| Q3 25 | — | $15.2B | ||
| Q2 25 | $29.6B | $15.6B | ||
| Q1 25 | — | $15.7B | ||
| Q4 24 | — | $18.6B | ||
| Q3 24 | — | $19.8B | ||
| Q2 24 | $30.1B | $19.5B | ||
| Q1 24 | — | $20.0B |
| Q4 25 | — | $37.2B | ||
| Q3 25 | — | $37.9B | ||
| Q2 25 | $108.7B | $38.4B | ||
| Q1 25 | — | $38.5B | ||
| Q4 24 | — | $41.5B | ||
| Q3 24 | — | $44.8B | ||
| Q2 24 | $100.9B | $45.3B | ||
| Q1 24 | — | $47.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2B | $815.8M |
| Free Cash FlowOCF − Capex | — | $619.3M |
| FCF MarginFCF / Revenue | — | 16.8% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | 4.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $815.8M | ||
| Q3 25 | — | $744.9M | ||
| Q2 25 | $1.2B | $219.7M | ||
| Q1 25 | — | $535.5M | ||
| Q4 24 | — | $482.7M | ||
| Q3 24 | — | $826.5M | ||
| Q2 24 | $1.1B | $379.1M | ||
| Q1 24 | — | $614.6M |
| Q4 25 | — | $619.3M | ||
| Q3 25 | — | $658.1M | ||
| Q2 25 | — | $166.8M | ||
| Q1 25 | — | $492.9M | ||
| Q4 24 | — | $342.3M | ||
| Q3 24 | — | $749.5M | ||
| Q2 24 | — | $320.3M | ||
| Q1 24 | — | $564.8M |
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 20.1% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 15.5% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.72× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.74× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIP
Segment breakdown not available.
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
